Atossa Therapeutics, Inc. (ATOS.MX)
Mexico · MXN · Healthcare · Biotechnology
MX$45.49 (-10.80%) as of
Key statistics
- Market cap
- 453.96M
- EPS (TTM)
- -89.77
- Dividend yield
- 0.00%
- 52-week range
- 31.00 – 256.50
- Beta
- 1.27
- Profit margin
- 0.00%
- Volume
- 538.00
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seattle, WA, United States
- Employees
- 16
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.